Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 23-24/2015

01.12.2015 | original article

Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease

verfasst von: MD, MSc Asst. Miroslav Vujasinovic, MD, PhD Prof. Bojan Tepes, MD Bojan Vujkovac, MD Andreja Cokan Vujkovac, MD, PhD Martin Tretjak, RN Vesna Korat

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Fabry disease (FD), also called Anderson–Fabry disease, is the second most prevalent lysosomal storage disorder after Gaucher disease. Gastrointestinal (GI) symptoms are very common among male and female individuals, although the age of onset is later among female patients. To our best knowledge, exocrine pancreatic insufficiency (EPI) has not yet been studied in patients with FD as a possible cause of abdominal complaints. The aim of our study was to determine whether exocrine pancreatic function is impaired in patients with FD.

Patients and methods

We analysed medical records of patients with FD treated in Fabry Center in Slovenj Gradec General Hospital (Slovenian referral centre for FD) by the evaluation of the following features: gender, age, first symptoms before confirmation of FD diagnosis, time interval between first symptoms and diagnosis, therapy and current abdominal complaints. Diagnosis of FD was established by genetic analysis and confirmation of mutation in the α-galactosidase A gene. Faecal elastase-1 (FE-1) measurements were performed using enzyme-linked immunosorbent assay and the commercial kit ScheBo Biotech, Giessen, Germany.

Results

There were 28 adult patients (Slovene, Caucasians) with known FD included in the study: 12 male and 16 female; mean age, 45.6 ± 14.3 (range, 19–75) years. Seventeen patients (63 %) were on enzyme replacement therapy (ERT). In seven (25.9 %) patients, abdominal complaints (diarrhoea, bloating and feeling of satiety) were present before introduction of ERT. In three out of these seven patients, abdominal complaints resolved after ERT, and in four patients, they were still occasionally present. FE-1 was normal in all patients (547.9 ± 104.5 µg/g).

Conclusions

Our results show that exocrine pancreatic function is normal in all patients with FD and is most likely not a cause of abdominal complaints in this group of patients. Nevertheless, EPI still could not be completely excluded as an aetiology factor for GI problems in patients with FD because all our patients with GI problems were treated with ERT. Therefore, a potential effect of ERT on EPI cannot be excluded. Further studies are necessary to determine the aetiology, especially in the group of naïve male patients.
Literatur
1.
Zurück zum Zitat Bassotti G, Bellini M, Pucciani F, Pucciani F, Bocchini R, Bove A, et al. An extended assessment of bowel habits in a general population. World J Gastroenterol. 2004;10:713–6. CrossRefPubMed Bassotti G, Bellini M, Pucciani F, Pucciani F, Bocchini R, Bove A, et al. An extended assessment of bowel habits in a general population. World J Gastroenterol. 2004;10:713–6. CrossRefPubMed
2.
Zurück zum Zitat Behhary S, Ellis L, Corey M, Marcon M, Durie P. How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease? J Pediatr. 2002;141:84–90. CrossRef Behhary S, Ellis L, Corey M, Marcon M, Durie P. How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease? J Pediatr. 2002;141:84–90. CrossRef
3.
Zurück zum Zitat Chang L, Toner BB, Fukudo S, Guthrie E, Locke GR, Norton NJ, et al. Gender, age, society, culture, and he patient’s perspective in the functional gastrointestinal disorders. Gastroenterology. 2006;130:1435–46. CrossRefPubMed Chang L, Toner BB, Fukudo S, Guthrie E, Locke GR, Norton NJ, et al. Gender, age, society, culture, and he patient’s perspective in the functional gastrointestinal disorders. Gastroenterology. 2006;130:1435–46. CrossRefPubMed
4.
Zurück zum Zitat Dehout F, Roland D, Treille de Granseigne S, Guillaume B, Van Maldergem L. Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease. J Inherit Metab Dis. 2004;27:499–505. CrossRefPubMed Dehout F, Roland D, Treille de Granseigne S, Guillaume B, Van Maldergem L. Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease. J Inherit Metab Dis. 2004;27:499–505. CrossRefPubMed
5.
Zurück zum Zitat Domínguez-Munoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol. 1995;90:1834–7. PubMed Domínguez-Munoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol. 1995;90:1834–7. PubMed
6.
Zurück zum Zitat Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539–48. CrossRefPubMed Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539–48. CrossRefPubMed
8.
Zurück zum Zitat Friedman LS, Kirkham SE, Thistlethwaite JR, Platika D, Kolodny EH, Schuffler MD. Jejunal diverticulosis with perforation as a complication of Fabry’s disease. Gastroenterology. 1984;86:558–63. PubMed Friedman LS, Kirkham SE, Thistlethwaite JR, Platika D, Kolodny EH, Schuffler MD. Jejunal diverticulosis with perforation as a complication of Fabry’s disease. Gastroenterology. 1984;86:558–63. PubMed
10.
Zurück zum Zitat Gullo L, Ventrucci M, Tomassetti P, Migliori M, Pezzili R. Fecal elastase 1 determination in chronic pancreatitis. Dig Dis Sci. 1999;44:210–3. CrossRefPubMed Gullo L, Ventrucci M, Tomassetti P, Migliori M, Pezzili R. Fecal elastase 1 determination in chronic pancreatitis. Dig Dis Sci. 1999;44:210–3. CrossRefPubMed
11.
Zurück zum Zitat Hoffmann B, Schwarz M, Mehta A, Keshav S, Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5:1447–53. CrossRefPubMed Hoffmann B, Schwarz M, Mehta A, Keshav S, Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5:1447–53. CrossRefPubMed
12.
Zurück zum Zitat Houge G, Skarbøvik AJ. Fabry disease—a diagnostic and therapeutic challenge. Tidsskr Nor Laegeforen. 2005;125:1004–6. PubMed Houge G, Skarbøvik AJ. Fabry disease—a diagnostic and therapeutic challenge. Tidsskr Nor Laegeforen. 2005;125:1004–6. PubMed
14.
Zurück zum Zitat Leeds JS, Hopper AD, Hurlstone DP, Edwards SJ, McAlindon ME, Lobo AJ, et al. Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? Aliment Pharmacol Ther. 2007;25:265–71. CrossRefPubMed Leeds JS, Hopper AD, Hurlstone DP, Edwards SJ, McAlindon ME, Lobo AJ, et al. Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? Aliment Pharmacol Ther. 2007;25:265–71. CrossRefPubMed
15.
Zurück zum Zitat Löhr JM. Exocrine pancreatic insufficiency. 2nd ed. Bremen: UNI-MED; 2010. Löhr JM. Exocrine pancreatic insufficiency. 2nd ed. Bremen: UNI-MED; 2010.
16.
Zurück zum Zitat Löser C, Möllgaard, Fölsch UR. Faecal elastase 1: a novel, highly sensitive and specific tubeless pancreatic function test. Gut. 1996;39:580–6. PubMedCentralCrossRefPubMed Löser C, Möllgaard, Fölsch UR. Faecal elastase 1: a novel, highly sensitive and specific tubeless pancreatic function test. Gut. 1996;39:580–6. PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–60. PubMedCentralCrossRefPubMed MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–60. PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54. CrossRefPubMed Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54. CrossRefPubMed
19.
Zurück zum Zitat O’Brien BD, Shnitka TK, McDougall R, Walker K, Costopoulos L, Lentle B, et al. Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry’s disease. Gastroenterology. 1982;82:957–62. PubMed O’Brien BD, Shnitka TK, McDougall R, Walker K, Costopoulos L, Lentle B, et al. Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry’s disease. Gastroenterology. 1982;82:957–62. PubMed
20.
Zurück zum Zitat Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151–6. CrossRefPubMed Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151–6. CrossRefPubMed
21.
Zurück zum Zitat Rowe JW, Gilliam JI, Warthin TA. Intestinal manifestations of Fabry’s disease. Ann Intern Med. 1974;81:628–31. CrossRefPubMed Rowe JW, Gilliam JI, Warthin TA. Intestinal manifestations of Fabry’s disease. Ann Intern Med. 1974;81:628–31. CrossRefPubMed
22.
Zurück zum Zitat Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol. 1981;76:246–51. PubMed Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol. 1981;76:246–51. PubMed
23.
Zurück zum Zitat Toouli J, Biankin AV, Oliver MR, Pearce CB, Wilson JS, Wray NH. Australasian Pancreatic Club recommendations. Med J Aust. 2010;193:461–7. PubMed Toouli J, Biankin AV, Oliver MR, Pearce CB, Wilson JS, Wray NH. Australasian Pancreatic Club recommendations. Med J Aust. 2010;193:461–7. PubMed
24.
Zurück zum Zitat Tümer L, Ezgü FS, Hasanoğlu A, Dalgiç B, Bakkaloğlu SA, Memiş L, et al. The co- existence of Fabry and celiac disease: a case report. Pediatr Nephrol. 2004;19:679–81. CrossRefPubMed Tümer L, Ezgü FS, Hasanoğlu A, Dalgiç B, Bakkaloğlu SA, Memiş L, et al. The co- existence of Fabry and celiac disease: a case report. Pediatr Nephrol. 2004;19:679–81. CrossRefPubMed
25.
Zurück zum Zitat Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab. 2007;93:112–28. CrossRefPubMed Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab. 2007;93:112–28. CrossRefPubMed
Metadaten
Titel
Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease
verfasst von
MD, MSc Asst. Miroslav Vujasinovic
MD, PhD Prof. Bojan Tepes
MD Bojan Vujkovac
MD Andreja Cokan Vujkovac
MD, PhD Martin Tretjak
RN Vesna Korat
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 23-24/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0731-9